MAPT and Alzheimer disease: The current diagnostic tests for AD and FTD are dominated by the identification and quantification of Aβ, tau or phospho‐tau in the cerebrospinal fluid (CSF) (Blennow and Zetterberg 2018; Mattsson et al.